The B4GALT6 Knockout A-549 Polyclonal Cells represent a pooled population of human A-549 lung adenocarcinoma epithelial cells that have been subjected to CRISPR/Cas9-mediated disruption of the B4GALT6 gene. This product is supplied as a polyclonal knockout pool, providing a heterogeneous population with loss-of-function mutations in the target locus, which enables the study of B4GALT6 depletion in a genetically diverse cellular context. The polyclonal format allows researchers to interrogate the overall functional consequences of B4GALT6 ablation without the limitations of a single clonal isolate, thereby facilitating robust analysis of glycosylation-dependent processes in cancer.
The parental A-549 cell line was originally derived from a 58-year-old male with lung adenocarcinoma and is widely employed as a model of alveolar type II epithelium. A-549 cells are a cornerstone in cancer biology and toxicology research, exhibiting characteristic features of lung adenocarcinoma including anchorage-independent growth and tumorigenic potential. Their epithelial origin and retention of key signaling pathways make them a suitable platform for investigating the molecular mechanisms underlying non-small cell lung cancer progression, particularly those involving cell surface glycosylation alterations.
B4GALT6 encodes a beta-1,4-galactosyltransferase that transfers galactose from UDP-galactose (UDP-Gal) to glucosylceramide (GlcCer), forming lactosylceramide (LacCer). This reaction lies within the glycosphingolipid biosynthetic pathway, where UDP-glucose ceramide glucosyltransferase (UGCG) first produces GlcCer, then B4GALT6 generates LacCer, which serves as a precursor for gangliosides such as GM3 and GD3 synthesized by GM3 synthase (ST3GAL5). Upstream regulators including the SP1 transcription factor, retinoic acid signaling, and mTOR pathway modulate B4GALT6 expression. Interacting factors like calnexin aid protein folding, while association with other glycosyltransferases influences Golgi localization. Disruption of B4GALT6 impairs LacCer production, thereby altering the cell surface glycocalyx and affecting adhesion receptors and signaling platforms.
In the A-549 lung cancer context, loss of B4GALT6 function profoundly impacts cellular behavior by reducing lactosylceramide-dependent membrane microdomain organization. The resulting changes in glycosphingolipid composition can weaken integrin-mediated adhesion, modulate growth factor receptor signaling, and promote a more migratory and invasive phenotype, as suggested by the mechanistic link to metastasis. This model thus provides a relevant system to dissect the contribution of glycolipid synthesis to epithelial-mesenchymal transition and metastatic dissemination, while also allowing exploration of compensatory glycosylation pathways that may emerge in the absence of B4GALT6 activity.
Key applications include investigating glycosylation-dependent cancer phenotypes, dissecting glycolipid roles in migration and invasion via Transwell assays, and screening glycosyltransferase-targeted therapeutics. Complementary assays comprise LC-MS-based lactosylceramide quantification, lectin blotting, and flow cytometry for surface glycosphingolipids, alongside MTT viability testing in a glycosylation-compromised context. For further details, contact Ascent Research.
